What Are Negative Margins in SFT Surgery?
Published: | Updated:
In SFT surgery, a negative margin (R0) means the entire tumor and a healthy tissue border were removed, with no tumor cells at the edges. This is the most critical factor for preventing local recurrence, though long-term monitoring remains essential.
Key Takeaways
- • A negative margin means the solitary fibrous tumor was removed completely along with a protective border of healthy tissue.
- • Pathologists coat the removed tissue in medical ink; if no tumor cells touch the ink under a microscope, it is considered a negative margin (R0).
- • Positive margins (R1 or R2) indicate that tumor cells were left behind, which increases the risk of the tumor returning in the same spot.
- • If negative margins cannot be achieved safely, doctors may recommend additional treatments like radiation therapy.
- • Long-term monitoring with imaging scans is required for all SFT patients, even when surgery achieves perfect negative margins.
When your surgeon says they need to get “negative margins,” they mean they must remove the solitary fibrous tumor (SFT) along with a continuous border (or “margin”) of healthy, normal tissue surrounding it. Achieving a negative margin means the entire tumor and a protective border of healthy tissue have been removed, significantly reducing the chance that microscopic tumor cells remain at the surgical site. This is the most critical factor in preventing the tumor from growing back in the same spot, which is known as local recurrence.
How Do They Know the Margins Are Negative?
During surgery, the tumor and the surrounding rim of normal tissue are removed in one piece. The width of this healthy border varies greatly depending on where the tumor is located; in some areas, surgeons can take a wide margin, while in others, they can only take a few millimeters to protect vital organs.
Once the tissue is removed, a doctor called a pathologist examines it. Processing the tissue and reviewing it takes time, so you generally will not know your margin status immediately after waking up from surgery; it usually takes several days to a week to get the pathology report.
The pathologist coats the outer edges of the removed tissue with a special medical ink [1][2]. They then slice the tissue into thin sections and look at representative slices under a microscope. If the tumor cells are entirely inside the healthy tissue and do not touch the ink, it is called a negative margin or an R0 resection [1][2].
If tumor cells are found touching the ink, it means the tumor went right up to the edge of what was removed. This is called a positive margin (or R1 if only seen under a microscope), which suggests that microscopic tumor cells may have been left behind in the body [2][1]. If a surgeon can clearly see that part of the tumor was left behind during surgery, it is known as a macroscopic positive margin or R2 [2][1].
Why Achieving Negative Margins Matters
A complete surgical removal with negative margins is the gold standard and most important treatment for an SFT [3][4]. When tumor cells are left behind (a positive margin), there is a significantly higher risk that the SFT will grow back in that same location [2][5].
Your margin status is also a key piece of information that doctors use, along with factors like the size of the tumor and how fast the cells are dividing (often called the mitotic rate or mitotic count), to predict how your SFT will behave and to create your long-term care plan [2][6][7].
What Happens if Margins Are Positive?
Sometimes, a tumor is located too close to vital blood vessels, nerves, or organs, making it impossible for the surgeon to remove a wide border of healthy tissue safely. If your margins are positive, your care team may discuss additional treatments, such as radiation therapy, to help lower the risk of the tumor returning [5][8][9].
Even when surgeons achieve perfect negative margins, SFTs are known to be unpredictable and can sometimes recur [10][11][12]. Furthermore, because pathologists look at representative slices rather than every single microscopic piece of tissue, micrometastases could potentially remain. Because of this, long-term monitoring with regular imaging scans is necessary for everyone who has had SFT surgery, regardless of their margin status [13][14].
Frequently Asked Questions
What is a negative margin in SFT surgery?
What is the difference between R0, R1, and R2 margins?
How long does it take to find out my margin status?
Will I need radiation if my margins are positive?
Do I still need follow-up scans if I had a completely negative margin?
Questions for Your Doctor
- • What was my surgical margin status according to the pathology report (R0, R1, or R2)?
- • Given the location of my tumor, were you able to achieve the margin width you originally planned for?
- • How does my margin status combine with my mitotic rate to affect my overall risk score?
- • Based on my margin results, should we consider additional treatments like radiation therapy?
- • What is the specific imaging and follow-up schedule you recommend for monitoring me long-term?
Questions for You
- • Do I know who to contact on my care team to check when my final pathology report and margin status will be available?
- • Have I prepared myself for the reality that even with a successful surgery, I will need long-term monitoring?
- • What are my priorities if my margins are positive and we need to discuss further treatments like radiation?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
A Case of Solitary Fibrous Tumor in the Pelvis Completely Resected Using the Hugo RAS System.
Toyota M, Miyo M, Okuya K, et al.
Journal of the anus, rectum and colon 2025; (9(3)):362-367 doi:10.23922/jarc.2025-027.
PMID: 40740760 - 2
Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers.
Ghanim B, Hess S, Bertoglio P, et al.
Scientific reports 2017; (7(1)):12557 doi:10.1038/s41598-017-12914-2.
PMID: 28970578 - 3
Hybrid Management of Giant Solitary Intracranial Fibrous Tumors: A Report of Two Cases.
Alvis Peña DJ, Morales Baez JA, Espinosa Lira F, et al.
Cureus 2025; (17(7)):e87798 doi:10.7759/cureus.87798.
PMID: 40799885 - 4
Outcome of surgery in patients with solitary fibrous tumors of the pleura.
Fattahi Masuom SH, Bagheri R, Sadrizadeh A, et al.
Asian cardiovascular & thoracic annals 2016; (24(1)):18-22 doi:10.1177/0218492315614977.
PMID: 26542951 - 5
Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients.
Li Q, Deng W, Sun P
World neurosurgery 2022; (166()):e60-e69 doi:10.1016/j.wneu.2022.06.089.
PMID: 35760325 - 6
Aggressive Behavior Predictors in Solitary Fibrous Tumor: Demographic, Clinical, and Histopathologic Characteristics of 81 Cases.
Hassani M, Jung S, Garzia L, et al.
Annals of surgical oncology 2021; (28(11)):6861-6867 doi:10.1245/s10434-021-09592-w.
PMID: 33512676 - 7
Comparison of published risk models for prediction of outcome in patients with extrameningeal solitary fibrous tumour.
Demicco EG, Griffin AM, Gladdy RA, et al.
Histopathology 2019; (75(5)):723-737 doi:10.1111/his.13940.
PMID: 31206727 - 8
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J, Stacchiotti S, Lopez-Pousa A, et al.
The Lancet. Oncology 2019; (20(1)):134-144 doi:10.1016/S1470-2045(18)30676-4.
PMID: 30578023 - 9
A Rare Metastatic Fibrous Tumor: Review of Literature With a Case Report.
Swaminathan G, Muratori J, Rauf F, et al.
JTO clinical and research reports 2025; (6(12)):100901 doi:10.1016/j.jtocrr.2025.100901.
PMID: 41399740 - 10
Malignant extrapleural solitary fibrous tumor arising in the sublingual gland: A case report and review of literature.
Iorio B, Ronchi A, Montella M, et al.
Oral oncology 2019; (90()):141-144 doi:10.1016/j.oraloncology.2018.12.013.
PMID: 30638760 - 11
Grade III solitary fibrous tumor/hemangiopericytoma: An enthralling intracranial tumor-A case report and literature review.
Al Armashi AR, Alkrekshi A, Al Zubaidi A, et al.
Radiology case reports 2022; (17(10)):3792-3796 doi:10.1016/j.radcr.2022.07.007.
PMID: 35965927 - 12
Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.
Sagiv O, Bell D, Guo Y, et al.
Ophthalmic plastic and reconstructive surgery 2019; (35(2)):148-154 doi:10.1097/IOP.0000000000001189.
PMID: 30371551 - 13
Management of solitary fibrous tumours of the pleura: a systematic review and meta-analysis.
Mercer RM, Wigston C, Banka R, et al.
ERJ open research 2020; (6(3)) doi:10.1183/23120541.00055-2020.
PMID: 32832532 - 14
Solitary Fibrous Tumors of the Head and Neck: A Single-Institution Study of 52 Patients.
Chung HR, Tam K, Han AY, et al.
OTO open 2022; (6(3)):2473974X221098709 doi:10.1177/2473974X221098709.
PMID: 35845143
This page explains surgical margins and pathology terms for solitary fibrous tumors for educational purposes. Always consult your surgical oncologist or pathologist for interpretation of your specific pathology report and treatment plan.
Stay up to date
Get notified when new research about Solitary Fibrous Tumor (SFT) is published.
No spam. Unsubscribe anytime.